The global esoteric testing market size was valued at USD 20,218.60 Million in 2020, and is estimated to reach USD 66,214.79 Million by 2030, growing at a CAGR of 12.5% from 2021 to 2030. Growth of the global esoteric testing market is majorly driven by an increase in prevalence of chronic, infectious, and rare genetic disease.
Esoteric testing is a laboratory analysis of rare molecule and substance, which is not performed in a routine clinical laboratory. These tests are performed when a physician requires some addition and detailed information about the patient's health condition. It requires a sophisticated instrument & materials and skilled technician to analyze the result.
The COVID-19 outbreak is anticipated to have a positive impact on growth of the global esoteric testing market. The COVID-19 pandemic has stressed the healthcare systems in the world but increased the need for diagnostic service center and surged the demand for enzyme-linked immunosorbent assay (ELISA) and real-time polymerase chain reaction (RT-PCR) test to detect COVID-19.
Rise in demand for enzyme linked immunosorbent assay (ELISA) and real time polymerase chain reaction (RT-PCR); increase in funding from private & government organizations for the diagnostic service center; and advancement in technology for esoteric testing. According to the World Health Organization (WHO), in 2021, it was reported that 77% of the deaths from chronic diseases occur in low and middle income countries. For instance, in May 2021, Cipla Limited, an Indian multinational pharmaceutical company, launched ViraGen, an RT-PCR test kit for detection of COVID-19. It is a real-time detection kit, which is designed to detect and identify ORF Lab gene and SARS CoV-2 N gene having sensitivity of 98.6% and specificity of 98.8% as compared to the standard Indian Council of Medical Research (ICMR) test. In addition, rise in geriatric population who are more vulnerable to chronic diseases fuels the market growth during the forecast period. According to Beijing, in 2019, it was reported that over 180 million geriatric population in China was living with chronic diseases. In addition, in May 2021, Neuberg Diagnostic, a leading company that offers best-in-class laboratories, launched the clinical laboratory's operation in the U.S. to offer genomic and molecular testing on new generation sequencing technology.
Thus, technological advancement in esoteric testing and increase in number of diagnostic tests propel the growth of the esoteric testing market. However, the high cost associated with esoteric testing and lack of skilled technicians are expected to restrict the market growth during the forecast period.
The esoteric testing market is segmented on the basis of type, technology, end user, and region. By type, the market is categorized into infectious disease testing, oncology testing, endocrinology testing, genetic testing, toxicology testing, immunology testing, neurology testing, and other testing.
By technology, it is divided into enzyme-linked immunosorbent assay, chemiluminescence immunoassay, mass-spectrometry, real time polymerase chain reaction, DNA sequencing, flow cytometry, and other technologies. By end user, the market is fragmented into hospital-based laboratories and independent and reference laboratories. On the basis of hospital-based laboratories, the market is further classified into enzyme-linked immunosorbent assay, chemiluminescence immunoassay, mass-spectrometry, real time polymerase chain reaction, DNA sequencing, flow cytometry, and other technologies. By independent and reference laboratories, the market is further categorized into enzyme-linked immunosorbent assay, chemiluminescence immunoassay, mass-spectrometry, real time polymerase chain reaction, DNA sequencing, flow cytometry, and other technologies.
Region-wise, the esoteric testing market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Depending on type, the infectious disease testing segment dominated the market in 2020, and is expected to continue this trend during the forecast period, owing to increase in prevalence of infection disease, development in healthcare laboratory, and advancements in technology for molecular diagnostic. However, the genetic testing segment is expected to witness considerable market growth during the forecast period, owing to increase in prevalence of genetic diseases, surge in demand for stem cell research activities, and increase in demand for genomic models.
On the basis of technology, the chemiluminescence immunoassay segment dominated the esoteric testing market in 2020, and is expected to continue this trend during the forecast period, owing to increase in prevalence of chronic disease such as autoimmune disease, diabetics, heart disease, and cancer; surge in awareness about early diagnostic of disease; and advancement in R&D for drug discovery and development activities. However, the DNA sequencing segment is expected to witness considerable growth during the forecast period, owing to increase in prevalence of infectious disease, such as hepatitis, neurological disorders, dengue, cancer, and AIDS; rise in geriatric population; and surge in demand for cost-effective diagnostic testing service.
On the basis of end user, the independent and reference laboratories segment dominated the market in 2020, and is expected to continue this trend during the forecast period, owing to increase in number of laboratories, high testing volumes, and surge in digitalization of diagnostic laboratories. However, the hospital-based laboratories segment is expected to witness considerable growth during the forecast period due to rise in prevalence of chronic disease, development in hospital laboratories, and increasing need for preventive healthcare.
North America accounted for a major share in the esoteric testing market in 2020, and is expected to maintain its dominance during the forecast period, owing to rise in prevalence of chronic disease and increase in number of diagnostic tests and technological advancement for esoteric testing. However, Asia-Pacific is expected to register the highest CAGR of 13.4% from 2021 to 2030, owing to increase in prevalence of chronic disease, rise in government initiative for diagnostic service, surge in demand for ELISA and RT-PCR test, and increase in awareness among population for self-diagnostic testing.
Key players operating in the global esoteric testing market include ARUP Laboratories, Baylor Esoteric and Molecular Laboratory, Foundation Medicine, Healius Limited, Laboratory Corporation, Mayo Foundation for Medical Education and Research, OPKO Health, Quest Diagnostics, Sonic Healthcare Limited, and Stanford Clinical Pathology.
|
Report Metric |
Details |
|
Report Name |
Esoteric Testing Market |
|
Market size value in 2020 |
USD 20,218.60 Million |
|
Revenue forecast in 2030 |
USD 66,214.79 Million |
|
Growth Rate |
CAGR 12.5% |
|
Base year considered |
2020 |
|
Historical Data for |
2021-2030 |
|
Segment by Type |
Infectious Disease Testing, Oncology Testing, Endocrinology Testing, Genetic Testing, Toxicology Testing, Immunology Testing, Neurology Testing, and Other Testing |
|
Segment by Technology |
Enzyme-Linked Immunosorbent Assay, Chemiluminescence Immunoassay, Mass-Spectrometry, Real Time Polymerase Chain Reaction, DNA Sequencing, Flow Cytometry, and Other Technologies |
|
Segment by End user |
Hospital-based Laboratories and Independent and Reference Laboratories |
Ans: The global esoteric testing market size was valued at USD 20,218.60 Million in 2020 and is estimated to reach USD 66,214.79 Million by 2030, growing at a CAGR of 12.5% from 2021 to 2030.
Ans: North America accounted for a large share of the esoteric testing market in 2020, and it is expected to maintain its dominance during the forecast period, owing to rise in the prevalence of chronic disease, the increase in the number of diagnostic tests, and technological advancement in esoteric testing.
Ans: Key players operating in the global esoteric testing market include ARUP Laboratories, Baylor Esoteric and Molecular Laboratory, Foundation Medicine, Healius Limited, Laboratory Corporation, Mayo Foundation for Medical Education and Research, OPKO Health, Quest Diagnostics, Sonic Healthcare Limited, and Stanford Clinical Pathology.
Ans: An increase in the prevalence of chronic, infectious, and rare genetic disease; rise in demand for enzyme-linked immunosorbent assay (ELISA) and real-time polymerase chain reaction (RT-PCR) is expected to increase the market growth.
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s five forces analysis
3.4.Top player positioning, 2020
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Surge in prevalence of chronic, infectious and genetic diseases
3.5.1.2.Increase in demand for ELISA and RT-PCR test
3.5.1.3.Increasing in number of medical laboratories
3.5.1.4.Growth in awareness among individual regarding early diagnosis detection and personalized medicine
3.5.2.Restraints
3.5.2.1.High cost for esoteric testing
3.5.2.2.Lack of skilled professionals & laboratory technicians
3.5.3.Opportunity
3.5.3.1.Rise in technological advancement in esoteric testing
3.5.4.Impact analysis
3.6.Impact analysis of COVID-19 on the Esoteric testing market
CHAPTER 4:ESOTERIC TESTING MARKET, BY TYPE
4.1.Overview
4.1.1.Market size and forecast
4.2.Infectious disease testing
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Oncology Testing
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.4.Endocrinology Testing
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country
4.5.Genetic testing
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country
4.6.Toxicology Testing
4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast, by region
4.6.3.Market analysis, by country
4.7.Immunology Testing
4.7.1.Key market trends, growth factors, and opportunities
4.7.2.Market size and forecast, by region
4.7.3.Market analysis, by country
4.8.Neurology testing
4.8.1.Key market trends, growth factors, and opportunities
4.8.2.Market size and forecast, by region
4.8.3.Market analysis, by country
4.9.Other Testing
4.9.1.Key market trends, growth factors, and opportunities
4.9.2.Market size and forecast, by region
4.9.3.Market analysis, by country
CHAPTER 5:ESOTERIC TESTING MARKET, BY TECHNOLOGY
5.1.Overview
5.1.1.Market size and forecast
5.2.Enzyme-linked immunosorbent assay
5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market size and forecast, by region
5.2.3.Market analysis, by country
5.3.Chemiluminescence Immunoassay
5.3.1.Key market trends, growth factors, and opportunities
5.3.2.Market size and forecast, by region
5.3.3.Market analysis, by country
5.4.Mass Spectrometry
5.4.1.Key market trends, growth factors, and opportunities
5.4.2.Market size and forecast, by region
5.4.3.Market analysis, by country
5.5.Real-time polymerase chain reaction
5.5.1.Key market trends, growth factors, and opportunities
5.5.2.Market size and forecast, by region
5.5.3.Market analysis, by country
5.6.DNA sequencing
5.6.1.Key market trends, growth factors, and opportunities
5.6.2.Market size and forecast, by region
5.6.3.Market analysis, by country
5.7.Flow cytometry
5.7.1.Key market trends, growth factors, and opportunities
5.7.2.Market size and forecast, by region
5.7.3.Market analysis, by country
5.8.Other technologies
5.8.1.Key market trends, growth factors, and opportunities
5.8.2.Market size and forecast, by region
5.8.3.Market analysis, by country
CHAPTER 6:ESOTERIC TESTING MARKET, BY END USER
6.1.Overview
6.1.1.Market size and forecast
6.2.Hospital-based laboratories
6.2.1.Key market trends, growth factors, and opportunities
6.2.2.Market size and forecast, by region
6.2.3.Market analysis, by country
6.2.4.Hospital-based laboratories, by technology
6.3.Independent & reference laboratories
6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market size and forecast, by region
6.3.3.Market analysis, by country
6.3.4.Independent & reference laboratories, by technology
CHAPTER 7:ESOTERIC TESTING MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.North America esoteric testing market, by type
7.2.3.North America esoteric testing market, by technology
7.2.4.North America esoteric testing market, by end user
7.2.5.Market size and forecast, by country
7.2.5.1.U.S.
7.2.5.1.1.U.S. esoteric testing market, by type
7.2.5.1.2.U.S. esoteric testing market, by technology
7.2.5.1.3.U.S. esoteric testing market, by end user
7.2.5.2.Canada
7.2.5.2.1.Canada esoteric testing market, by type
7.2.5.2.2.Canada esoteric testing market, by technology
7.2.5.2.3.Canada esoteric testing market, by end user
7.2.5.3.Mexico
7.2.5.3.1.Mexico esoteric testing market, by type
7.2.5.3.2.Mexico esoteric testing market, by technology
7.2.5.3.3.Mexico esoteric testing market, by end user
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Europe esoteric testing market, by type
7.3.3.Europe esoteric testing market, by technology
7.3.4.Europe esoteric testing market, by end user
7.3.5.Market size and forecast, by country
7.3.5.1.Germany
7.3.5.1.1.Germany esoteric testing market, by type
7.3.5.1.2.Germany esoteric testing market, by technology
7.3.5.1.3.Germany esoteric testing market, by end user
7.3.5.2.France
7.3.5.2.1.France esoteric testing market, by type
7.3.5.2.2.France esoteric testing market, by technology
7.3.5.2.3.France esoteric testing market, by end user
7.3.5.3.UK
7.3.5.3.1.UK esoteric testing market, by type
7.3.5.3.2.UK esoteric testing market, by technology
7.3.5.3.3.UK esoteric testing market, by end user
7.3.5.4.Italy
7.3.5.4.1.Italy esoteric testing market, by type
7.3.5.4.2.Italy esoteric testing market, by technology
7.3.5.4.3.Italy esoteric testing market, by end user
7.3.5.5.Spain
7.3.5.5.1.Spain esoteric testing market, by type
7.3.5.5.2.Spain esoteric testing market, by technology
7.3.5.5.3.Spain esoteric testing market, by end user
7.3.5.6.Rest of Europe
7.3.5.6.1.Rest of Europe esoteric testing market, by type
7.3.5.6.2.Rest of Europe esoteric testing market, by technology
7.3.5.6.3.Rest of Europe esoteric testing market, by end user
7.4.Asia-Pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Asia-Pacific esoteric testing market, by type
7.4.3.Asia-Pacific esoteric testing market, by technology
7.4.4.Asia-Pacific esoteric testing market, by end user
7.4.5.Market size and forecast, by country
7.4.5.1.Japan
7.4.5.1.1.Japan esoteric testing market, by type
7.4.5.1.2.Japan esoteric testing market, by technology
7.4.5.1.3.Japan esoteric testing market, by end user
7.4.5.2.China
7.4.5.2.1.China esoteric testing market, by type
7.4.5.2.2.China esoteric testing market, by technology
7.4.5.2.3.China esoteric testing market, by end user
7.4.5.3.Australia
7.4.5.3.1.Australia esoteric testing market, by type
7.4.5.3.2.Australia esoteric testing market, by technology
7.4.5.3.3.Australia esoteric testing market, by end user
7.4.5.4.India
7.4.5.4.1.India esoteric testing market, by type
7.4.5.4.2.India esoteric testing market, by technology
7.4.5.4.3.India esoteric testing market, by end user
7.4.5.5.Rest of Asia-Pacific
7.4.5.5.1.Rest of Asia-Pacific esoteric testing market, by type
7.4.5.5.2.Rest of Asia-Pacific esoteric testing market, by technology
7.4.5.5.3.Rest of Asia-Pacific esoteric testing market, by end user
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.LAMEA esoteric testing market, by type
7.5.3.LAMEA esoteric testing market, by technology
7.5.4.LAMEA esoteric testing market, by end user
7.5.5.Market size and forecast, by country
7.5.5.1.Brazil
7.5.5.1.1.Brazil esoteric testing market, by type
7.5.5.1.2.Brazil esoteric testing market, by technology
7.5.5.1.3.Brazil esoteric testing market, by end user
7.5.5.2.Saudi Arabia
7.5.5.2.1.Saudi Arabia esoteric testing market, by type
7.5.5.2.2.Saudi Arabia esoteric testing market, by technology
7.5.5.2.3.Saudi Arabia esoteric testing market, by end user
7.5.5.3.South Africa
7.5.5.3.1.South Africa esoteric testing market, by type
7.5.5.3.2.South Africa esoteric testing market, by technology
7.5.5.3.3.South Africa esoteric testing market, by end user
7.5.5.4.Rest of LAMEA
7.5.5.4.1.Rest of LAMEA esoteric testing market, by type
7.5.5.4.2.Rest of LAMEA esoteric testing market, by technology
7.5.5.4.3.Rest of LAMEA esoteric testing market, by end user
CHAPTER 8:COMPANY PROFILES
8.1.ARUP Laboratories
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Key strategic moves and developments
8.2.Baylor Esoteric and Molecular Laboratory
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.3.Foundation Medicine, Inc.
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Key strategic moves and developments
8.4.Healius Limited
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments
8.5.Laboratory Corporation
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.5.6.Key strategic moves and developments
8.6.Mayo Foundation for Medical Education and Research
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.7.OPKO Health Inc., (OPK)
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments
8.8.Quest Diagnostics
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments
8.9.Sonic Healthcare Limited
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments
8.10.Stanford Clinical Pathology
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
8.10.6.Key strategic moves and developments
LIST OF TABLES
TABLE 01.ESOTERIC TESTING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 02.ESOTERIC TESTING MARKET FOR INFECTIOUS DISEASE TESTING, BY REGION, 2020–2030 ($MILLION)
TABLE 03.ESOTERIC TESTING MARKET FOR ONCOLOGY TESTING, BY REGION, 2020–2030 ($MILLION)
TABLE 04.ESOTERIC TESTING MARKET FOR ENDOCRINOLOGY TESTING, BY REGION, 2020–2030 ($MILLION)
TABLE 05.ESOTERIC TESTING MARKET FOR GENETIC TESTING, BY REGION, 2020–2030 ($MILLION)
TABLE 06.ESOTERIC TESTING MARKET FOR TOXICOLOGY TESTING, BY REGION, 2020–2030 ($MILLION)
TABLE 07.ESOTERIC TESTING MARKET FOR IMMUNOLOGY TESTING, BY REGION, 2020–2030 ($MILLION)
TABLE 08.ESOTERIC TESTING MARKET FOR NEUROLOGY TESTING, BY REGION, 2020–2030 ($MILLION)
TABLE 09.ESOTERIC TESTING MARKET FOR OTHER TESTING, BY REGION, 2020–2030 ($MILLION)
TABLE 10.GLOBAL ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2020–2030 ($MILLION)
TABLE 11.ESOTERIC TESTING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2020–2030 ($MILLION)
TABLE 12.ESOTERIC TESTING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2020–2030 ($MILLION)
TABLE 13.ESOTERIC TESTING MARKET FOR MASS SPECTROMETRY, BY REGION, 2020–2030 ($MILLION)
TABLE 14.ESOTERIC TESTING MARKET FOR REAL-TIME POLYMERASE CHAIN REACTION, BY REGION, 2020–2030 ($MILLION)
TABLE 15.ESOTERIC TESTING MARKET FOR DNA SEQUENCING, BY REGION, 2020–2030 ($MILLION)
TABLE 16.ESOTERIC TESTING MARKET FOR FLOW CYTOMETRY, BY REGION, 2020–2030 ($MILLION)
TABLE 17.ESOTERIC TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020–2030 ($MILLION)
TABLE 18.GLOBAL ESOTERIC TESTING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 19.ESOTERIC TESTING MARKET FOR HOSPITAL-BASED LABORATORIES, BY REGION, 2020–2030 ($MILLION)
TABLE 20.HOSPITAL-BASED LABORATORIES, BY TECHNOLOGY, 2020–2030 ($MILLION)
TABLE 21.ESOTERIC TESTING MARKET FOR INDEPENDENT & REFERENCE LABORATORIES, BY REGION, 2020–2030 ($MILLION)
TABLE 22.INDEPENDENT & REFERENCE LABORATORIES, BY TECHNOLOGY, 2020–2030 ($MILLION)
TABLE 23.ESOTERIC TESTING MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 24.NORTH AMERICA ESOTERIC TESTING MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 25.NORTH AMERICA ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 26.NORTH AMERICA ESOTERIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 27.NORTH AMERICA ESOTERIC TESTING MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 28.U.S. ESOTERIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 29.U.S. ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 30.U.S. ESOTERIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 31.CANADA ESOTERIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 32.CANADA ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 33.CANADA ESOTERIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 34.MEXICO ESOTERIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 35.MEXICO ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 36.MEXICO ESOTERIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 37.EUROPE ESOTERIC TESTING MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 38.EUROPE ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 39.EUROPE ESOTERIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 40.EUROPE ESOTERIC TESTING MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 41.GERMANY ESOTERIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 42.GERMANY ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 43.GERMANY ESOTERIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 44.FRANCE ESOTERIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 45.FRANCE ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 46.FRANCE ESOTERIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 47.UK ESOTERIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 48.UK ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 49.UK ESOTERIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 50.ITALY ESOTERIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 51.ITALY ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 52.ITALY ESOTERIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 53.SPAIN ESOTERIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 54.SPAIN ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 55.SPAIN ESOTERIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 56.REST OF EUROPE ESOTERIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 57.REST OF EUROPE ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 58.REST OF EUROPE ESOTERIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 59.ASIA-PACIFIC ESOTERIC TESTING MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 60.ASIA-PACIFIC ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 61.ASIA-PACIFIC ESOTERIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 62.ASIA-PACIFIC ESOTERIC TESTING MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 63.JAPAN ESOTERIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 64.JAPAN ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 65.JAPAN ESOTERIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 66.CHINA ESOTERIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 67.CHINA ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 68.CHINA ESOTERIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 69.AUSTRALIA ESOTERIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 70.AUSTRALIA ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 71.AUSTRALIA ESOTERIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 72.INDIA ESOTERIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 73.INDIA ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 74.INDIA ESOTERIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 75.REST OF ASIA-PACIFIC ESOTERIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 76.REST OF ASIA-PACIFIC ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 77.REST OF ASIA-PACIFIC ESOTERIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 78.LAMEA ESOTERIC TESTING MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 79.LAMEA ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 80.LAMEA ESOTERIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 81.LAMEA ESOTERIC TESTING MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 82.BRAZIL ESOTERIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 83.BRAZIL ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 84.BRAZIL ESOTERIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 85.SAUDI ARABIA ESOTERIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 86.SAUDI ARABIA ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 87.SAUDI ARABIA ESOTERIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 88.SOUTH AFRICA ESOTERIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 89.SOUTH AFRICA ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 90.SOUTH AFRICA ESOTERIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 91.REST OF LAMEA ESOTERIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 92.REST OF LAMEA ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 93.REST OF LAMEA ESOTERIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 94.ARUP: COMPANY SNAPSHOT
TABLE 95.ARUP: OPERATING SEGMENTS
TABLE 96.ARUP: PRODUCT PORTFOLIO
TABLE 97.ARUP: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 98.BEM LAB: COMPANY SNAPSHOT
TABLE 99.BEM LAB: OPERATING SEGMENTS
TABLE 100.BEM LAB: PRODUCT PORTFOLIO
TABLE 101.FMI: COMPANY SNAPSHOT
TABLE 102.FMI: OPERATING SEGMENTS
TABLE 103.FMI: PRODUCT PORTFOLIO
TABLE 104.FMI: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 105.HEALIUS: COMPANY SNAPSHOT
TABLE 106.HEALIUS: OPERATING SEGMENTS
TABLE 107.HEALIUS: PRODUCT PORTFOLIO
TABLE 108.HEALIUS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 109.LABCORP: COMPANY SNAPSHOT
TABLE 110.LABCORP: OPERATING SEGMENTS
TABLE 111.LABCORP: PRODUCT PORTFOLIO
TABLE 112.LABCORP: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 113.MFMER: COMPANY SNAPSHOT
TABLE 114.MFMER: OPERATING SEGMENTS
TABLE 115.MFMER: PRODUCT PORTFOLIO
TABLE 116.OPK: COMPANY SNAPSHOT
TABLE 117.OPK: OPERATING SEGMENTS
TABLE 118.OPK: PRODUCT PORTFOLIO
TABLE 119.OPK: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 120.QUEST DIAGNOSTICS: COMPANY SNAPSHOT
TABLE 121.QUEST DIAGNOSTICS: OPERATING SEGMENTS
TABLE 122.QUEST DIAGNOSTICS: PRODUCT PORTFOLIO
TABLE 123.QUEST DIAGNOSTICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 124.SONIC: COMPANY SNAPSHOT
TABLE 125.SONIC: OPERATING SEGMENTS
TABLE 126.SONIC: PRODUCT PORTFOLIO
TABLE 127.SONIC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 128.STANFORD: COMPANY SNAPSHOT
TABLE 129.STANFORD: OPERATING SEGMENTS
TABLE 130.STANFORD: PRODUCT PORTFOLIO
TABLE 131.STANFORD: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 01.ESOTERIC TESTING MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018–2020
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018–2020
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018–2020
FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE THREAT OF SUBSTITUTES
FIGURE 09.HIGH THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE INTENSITY OF RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.COMPARATIVE ANALYSIS OF ESOTERIC TESTING MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2020–2030 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF ESOTERIC TESTING MARKET FOR ONCOLOGY TESTING, BY COUNTRY, 2020–2030 (%)
FIGURE 15.COMPARATIVE ANALYSIS OF ESOTERIC TESTING MARKET FOR ENDOCRINOLOGY TESTING, BY COUNTRY, 2020–2030 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF ESOTERIC TESTING MARKET FOR GENETIC TESTING, BY COUNTRY, 2020–2030 (%)
FIGURE 17.COMPARATIVE ANALYSIS OF ESOTERIC TESTING MARKET FOR TOXICOLOGY TESTING, BY COUNTRY, 2020–2030 (%)
FIGURE 18.COMPARATIVE ANALYSIS OF ESOTERIC TESTING MARKET FOR IMMUNOLOGY TESTING, BY COUNTRY, 2020–2030 (%)
FIGURE 19.COMPARATIVE ANALYSIS OF ESOTERIC TESTING MARKET FOR NEUROLOGY TESTING, BY COUNTRY, 2020–2030 (%)
FIGURE 20.COMPARATIVE ANALYSIS OF ESOTERIC TESTING MARKET FOR OTHER TESTING, BY COUNTRY, 2020–2030 (%)
FIGURE 21.COMPARATIVE ANALYSIS OF ESOTERIC TESTING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2020–2030 (%)
FIGURE 22.COMPARATIVE ANALYSIS OF ESOTERIC TESTING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2020–2030 (%)
FIGURE 23.COMPARATIVE ANALYSIS OF ESOTERIC TESTING MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2020–2030 (%)
FIGURE 24.COMPARATIVE ANALYSIS OF ESOTERIC TESTING MARKET FOR REAL-TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2020–2030 (%)
FIGURE 25.COMPARATIVE ANALYSIS OF ESOTERIC TESTING MARKET FOR DNA SEQUENCING, BY COUNTRY, 2020–2030 (%)
FIGURE 26.COMPARATIVE ANALYSIS OF ESOTERIC TESTING MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2020–2030 (%)
FIGURE 27.COMPARATIVE ANALYSIS OF ESOTERIC TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2020–2030 (%)
FIGURE 28.COMPARATIVE ANALYSIS OF ESOTERIC TESTING MARKET FOR HOSPITAL-BASED LABORATORIES, BY COUNTRY, 2020–2030 (%)
FIGURE 29.COMPARATIVE ANALYSIS OF ESOTERIC TESTING MARKET FOR INDEPENDENT & REFERENCE LABORATORIES, BY COUNTRY, 2020–2030 (%)
FIGURE 30.HEALIUS: NET SALES, 2018–2020 ($MILLION)
FIGURE 31.HEALIUS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 32.LABCORP: NET SALES, 2018–2020 ($MILLION)
FIGURE 33.LABCORP: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 34.LABCORP: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 35.MFMER: NET SALES, 2018–2020 ($MILLION)
FIGURE 36.OPK: NET SALES, 2018–2020 ($MILLION)
FIGURE 37.OPK: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 38.QUEST DIAGNOSTICS: NET SALES, 2018–2020 ($MILLION)
FIGURE 39.QUEST DIAGNOSTICS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 40.SONIC: NET SALES, 2018–2020 ($MILLION)
FIGURE 41.SONIC HEALTHCARE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 42.SONIC: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 43.STANFORD: NET SALES, 2018–2020 ($MILLION)
$6168
$10663
HAVE A QUERY?
OUR CUSTOMER
SIMILAR REPORTS